GlaxoSmithKline PLC — Director's Dealing 2012

Mar 12, 2012

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For period ending March 2012

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the interests of a Person Discharging Managerial Responsibility (PDMR), in the Ordinary Shares of GlaxoSmithKline plc as a result of an award made under the GlaxoSmithKline 2009 Performance Share Plan (Performance Share Plan) on 9 March 2012 as follows:

Name of PDMR	Ordinary shares
Mrs V Whyte	11,800

The GlaxoSmithKline 2009 Performance Share Plan award was based on an Ordinary Share price of £14.12 per share , (the closing middle market price of an Ordinary Share in GlaxoSmithKline plc on 8 March 2012). Vesting of the award is subject to meeting performance criteria over a three year period.

The Company and the above named person were advised of this transaction on 9 March 2012.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

12 March 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc

(Registrant)

Date: March 12, 2012

By: VICTORIA WHYTE

---

Victoria Whyte

Authorised Signatory for and on

behalf of GlaxoSmithKline plc